Håkan Hanberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Håkan Hanberger has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
- Kristoffer Strålin
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
7 shared publications Sten Walther
Swedish Intensive Care Registry, Värmland County Council
6 shared publications- Christian G. Giske
Clinical Microbiology, MTC – Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
5 shared publications - Erik Wahlström
National Board of Health and Welfare, Sweden
5 shared publications Anders Ternhag
Public Health Agency of Sweden
4 shared publicationsLennart E. Nilsson
Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Sweden
4 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (10)
Use of fomepizole as a novel approach for preventing aciclovir-induced neurotoxicity
- 1 September 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (10)
Open AccessUse of fomepizole as a novel approach for preventing aciclovir-induced neurotoxicity
- Open Access
- 10 December 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (12) , 1249
From 60 Causes to 10 Solutions Against Antibiotics Shortages in Sweden: Platinea’s Approach to Developing Policy Interventions
Background/Objectives: Antibiotic shortages are a growing problem which harms patient safety, increases healthcare costs, and accelerates antibiotic resistance. Based on the example of Sweden, the paper aims to illustrate and discuss how an organized collaboration platform can devise several policy interventions against shortages of antibiotics for human use. Methods: We describe how the multi-sectoral collaboration Platinea (Platform for Innovation of Existing Antibiotics) first identified, structured, and prioritized the causes of antibiotic shortages, and then identified and prioritized a set of policy solutions matching these causes. The specific methods applied include expert elicitation, interactive workshops, focus groups, and multi-criteria decision processes. Results: After an overview of about 60 causes of antibiotic shortages, we relate them to 10 prioritized solutions including, e.g., increased inventories, central coordination, integrated IT systems, increased unit prices, yearly fixed payments, and Nordic collaboration in purchasing and production. Conclusions: We propose a process with six steps to devise policy solutions by involving a multi-sectoral stakeholder group: open brainstorming of the problem’s causes, framing them into a clear structure, selecting and prioritizing key causes, matching causes and solutions, and devising prioritization mechanisms about emerging solutions. This approach can be applied to other national contexts and similar policy issues.
- 10 December 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (12) , 1249
Open AccessFrom 60 Causes to 10 Solutions Against Antibiotics Shortages in Sweden: Platinea’s Approach to Developing Policy Interventions
Background/Objectives: Antibiotic shortages are a growing problem which harms patient safety, increases healthcare costs, and accelerates antibiotic resistance. Based on the example of Sweden, the paper aims to illustrate and discuss how an organized collaboration platform can devise several policy interventions against shortages of antibiotics for human use. Methods: We describe how the multi-sectoral collaboration Platinea (Platform for Innovation of Existing Antibiotics) first identified, structured, and prioritized the causes of antibiotic shortages, and then identified and prioritized a set of policy solutions matching these causes. The specific methods applied include expert elicitation, interactive workshops, focus groups, and multi-criteria decision processes. Results: After an overview of about 60 causes of antibiotic shortages, we relate them to 10 prioritized solutions including, e.g., increased inventories, central coordination, integrated IT systems, increased unit prices, yearly fixed payments, and Nordic collaboration in purchasing and production. Conclusions: We propose a process with six steps to devise policy solutions by involving a multi-sectoral stakeholder group: open brainstorming of the problem’s causes, framing them into a clear structure, selecting and prioritizing key causes, matching causes and solutions, and devising prioritization mechanisms about emerging solutions. This approach can be applied to other national contexts and similar policy issues.
- Open Access
- 14 May 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (5) , e1269
Determination of Glomerular Filtration Rate After Contrast-Enhanced CT Among Critically Ill Patients: Support for a New Procedure
OBJECTIVES: To measure glomerular filtration rate using iohexol plasma clearance (mGFRiohexol) in critically ill patients using the high doses of iohexol administered at CT and to evaluate its agreements with urinary creatinine clearance (uClcr) and estimated glomerular filtration rates (eGFRs), calculated from plasma concentrations of creatinine (eGFRcr) and cystatin C (eGFRcys). DESIGN: Prospective observational cohort study. SETTING: ICUs across Southeast Sweden. PATIENTS: Critically ill adult patients. INTERVENTIONS AND MEASUREMENTS: Twenty-six ICU patients were given high doses of iohexol (range, 27–140 mL) for contrast-enhanced CT, whereafter blood samples were taken in the elimination phase for determination of mGFRiohexol. Plasma iohexol concentrations were determined by high-performance liquid chromatography and mGFRiohexol was calculated. Standard dose (5 mL) of iohexol was administered the following days to compare low-dose clearance results with the high-dose clearance results. Six-hour uClcr was performed four times a day and averaged. MAIN RESULTS: Mean ± sd mGFRiohexol after CT was 77.4 ± 38.1 mL/min (n = 26), and uClcr was 97.3 ± 58.2 mL/min (n = 25) in the critically ill patients. There was a strong positive correlation between mGFRiohexol determined with high and low doses of iohexol in patients with normal or high mGFRiohexol (coefficient of determination [R 2] = 0.88; p < 0.001) and between mGFRiohexol and uClcr (R 2 = 0.87; p < 0.001). eGFRcr overestimated mGFRiohexol and eGFRcys underestimated mGFRiohexol. CONCLUSIONS: mGFRiohexol after contrast-enhanced CT compares well with mGFRiohexol after standard low-dose iohexol respectively uClcr. Over- and underestimation of mGFRiohexol by eGFRcr and eGFRcys is probably explained by increased tubular secretion of creatinine and increased production of cystatin C in intensive care patients.
- 14 May 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (5) , e1269
Open AccessDetermination of Glomerular Filtration Rate After Contrast-Enhanced CT Among Critically Ill Patients: Support for a New Procedure
OBJECTIVES: To measure glomerular filtration rate using iohexol plasma clearance (mGFRiohexol) in critically ill patients using the high doses of iohexol administered at CT and to evaluate its agreements with urinary creatinine clearance (uClcr) and estimated glomerular filtration rates (eGFRs), calculated from plasma concentrations of creatinine (eGFRcr) and cystatin C (eGFRcys). DESIGN: Prospective observational cohort study. SETTING: ICUs across Southeast Sweden. PATIENTS: Critically ill adult patients. INTERVENTIONS AND MEASUREMENTS: Twenty-six ICU patients were given high doses of iohexol (range, 27–140 mL) for contrast-enhanced CT, whereafter blood samples were taken in the elimination phase for determination of mGFRiohexol. Plasma iohexol concentrations were determined by high-performance liquid chromatography and mGFRiohexol was calculated. Standard dose (5 mL) of iohexol was administered the following days to compare low-dose clearance results with the high-dose clearance results. Six-hour uClcr was performed four times a day and averaged. MAIN RESULTS: Mean ± sd mGFRiohexol after CT was 77.4 ± 38.1 mL/min (n = 26), and uClcr was 97.3 ± 58.2 mL/min (n = 25) in the critically ill patients. There was a strong positive correlation between mGFRiohexol determined with high and low doses of iohexol in patients with normal or high mGFRiohexol (coefficient of determination [R 2] = 0.88; p < 0.001) and between mGFRiohexol and uClcr (R 2 = 0.87; p < 0.001). eGFRcr overestimated mGFRiohexol and eGFRcys underestimated mGFRiohexol. CONCLUSIONS: mGFRiohexol after contrast-enhanced CT compares well with mGFRiohexol after standard low-dose iohexol respectively uClcr. Over- and underestimation of mGFRiohexol by eGFRcr and eGFRcys is probably explained by increased tubular secretion of creatinine and increased production of cystatin C in intensive care patients.
- Open Access
Risk factors for hospitalisation and death due to COVID-19 during endemic Omicron circulation, a population-based cohort study
Background Knowledge about risk factors for hospitalisation and death due to COVID-19 during the Omicron period, beyond the initial Omicron wave, remains limited. Therefore, to support vaccination strategies and antiviral treatment recommendations, we aimed to investigate the significance of various risk factors and their association with hospitalisation and death from COVID-19 during the Omicron period. Method Nationwide registry data on the Swedish adult population was compiled for the period June 6, 2022, to March 31, 2023. Frequency of hospitalisation with a primary discharge diagnosis of COVID-19 and death with COVID-19 specified as the underlying cause of death on the death certificate were analysed. Individual data were stratified by age, vaccination status, Charlson Comorbidity Index, and specific comorbidities. Poisson regression was used to estimate incidence risk ratios of independent risk factors for hospitalisation and death including age, sex, comorbidities, care dependency and socioeconomic factors. Results Among the more than 8,3 million individuals in the study cohort, 13 941 hospitalisations and 2 309 deaths due to COVID-19 were recorded during the study period. Multivariable analysis revealed that high age was the strongest risk factors for both hospitalisation and death. Advanced comorbidity was the second strongest risk factor for hospitalisation, and care dependency was the second strongest risk factor for death. Among comorbidities, recent chemotherapy, Immune Deficiency, Multiple Sclerosis, and Chronic Kidney Disease stage 5 were the strongest risk factors for hospitalisation and death. Conclusion Also in the current Omicron endemicity, advanced age remains the strongest risk factor for hospitalisation and death due to COVID-19, accompanied by advanced comorbidity and care dependency. These findings can guide recommendations for vaccination strategies and antiviral treatment, helping to protect those most at risk.
Open AccessRisk factors for hospitalisation and death due to COVID-19 during endemic Omicron circulation, a population-based cohort study
Background Knowledge about risk factors for hospitalisation and death due to COVID-19 during the Omicron period, beyond the initial Omicron wave, remains limited. Therefore, to support vaccination strategies and antiviral treatment recommendations, we aimed to investigate the significance of various risk factors and their association with hospitalisation and death from COVID-19 during the Omicron period. Method Nationwide registry data on the Swedish adult population was compiled for the period June 6, 2022, to March 31, 2023. Frequency of hospitalisation with a primary discharge diagnosis of COVID-19 and death with COVID-19 specified as the underlying cause of death on the death certificate were analysed. Individual data were stratified by age, vaccination status, Charlson Comorbidity Index, and specific comorbidities. Poisson regression was used to estimate incidence risk ratios of independent risk factors for hospitalisation and death including age, sex, comorbidities, care dependency and socioeconomic factors. Results Among the more than 8,3 million individuals in the study cohort, 13 941 hospitalisations and 2 309 deaths due to COVID-19 were recorded during the study period. Multivariable analysis revealed that high age was the strongest risk factors for both hospitalisation and death. Advanced comorbidity was the second strongest risk factor for hospitalisation, and care dependency was the second strongest risk factor for death. Among comorbidities, recent chemotherapy, Immune Deficiency, Multiple Sclerosis, and Chronic Kidney Disease stage 5 were the strongest risk factors for hospitalisation and death. Conclusion Also in the current Omicron endemicity, advanced age remains the strongest risk factor for hospitalisation and death due to COVID-19, accompanied by advanced comorbidity and care dependency. These findings can guide recommendations for vaccination strategies and antiviral treatment, helping to protect those most at risk.
- Open Access
- 3 April 2025
- Published by Taylor & Francis in Scandinavian Journal of Primary Health Care
- Vol. 43 (2) , 258-259
Letter to the editor
- 3 April 2025
- Published by Taylor & Francis in Scandinavian Journal of Primary Health Care
- Vol. 43 (2) , 258-259
Open AccessLetter to the editor
- Open Access
- 6 May 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (3) , dlae089
Evaluation of screening algorithms to detect rectal colonization with carbapenemase-producing Enterobacterales in a resource-limited setting
To improve and rationalize the detection of carbapenemase-producing Enterobacterales (CPE) in rectal swabs in a high-prevalence and resource-constrained setting, addressing surveillance challenges typically encountered in laboratories with limited resources. A point prevalence survey (PPS) was conducted on 15 August 2022, in a provincial children’s hospital in northern Vietnam. Rectal swab samples of all admitted children were collected and plated on a selective medium for carbapenem-resistant Enterobacterales (CRE). Species identification and antimicrobial susceptibility testing (AST) were performed by MALDI-TOF, and VITEK2 XL and interpreted according to CLSI breakpoints (2022). Carbapenemases were detected by the carbapenem inactivation method (CIM) and quantitative real-time PCR (qRT-PCR). Rectal swab samples were obtained from 376 patients. Of 178 isolates growing on the CRE screening agar, 140 isolates were confirmed as Enterobacterales of which 118 (84.3%) isolates were resistant to meropenem and/or ertapenem. CIM and PCR showed that 90/118 (76.3%) were carbapenemase producers. Overall, 83/367 (22.6%) were colonized by CPE. Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae complex were the most common CPE detected, with NDM as the predominant carbapenemase (78/90; 86.7%). Phenotypic resistance to meropenem was the best predictor of CPE production (sensitivity 85.6%, specificity 100%) compared with ertapenem resistance (95.6% sensitivity, 36% specificity). CIM was 100% concordant with PCR in detecting carbapenemases. These findings underscore the effectiveness of meropenem resistance as a robust indicator of the production of carbapenemases and the reliability of the CIM method to detect such carbapenemases in resource-limited settings where the performance of molecular methods is not possible.
- 6 May 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (3) , dlae089
Open AccessEvaluation of screening algorithms to detect rectal colonization with carbapenemase-producing Enterobacterales in a resource-limited setting
To improve and rationalize the detection of carbapenemase-producing Enterobacterales (CPE) in rectal swabs in a high-prevalence and resource-constrained setting, addressing surveillance challenges typically encountered in laboratories with limited resources. A point prevalence survey (PPS) was conducted on 15 August 2022, in a provincial children’s hospital in northern Vietnam. Rectal swab samples of all admitted children were collected and plated on a selective medium for carbapenem-resistant Enterobacterales (CRE). Species identification and antimicrobial susceptibility testing (AST) were performed by MALDI-TOF, and VITEK2 XL and interpreted according to CLSI breakpoints (2022). Carbapenemases were detected by the carbapenem inactivation method (CIM) and quantitative real-time PCR (qRT-PCR). Rectal swab samples were obtained from 376 patients. Of 178 isolates growing on the CRE screening agar, 140 isolates were confirmed as Enterobacterales of which 118 (84.3%) isolates were resistant to meropenem and/or ertapenem. CIM and PCR showed that 90/118 (76.3%) were carbapenemase producers. Overall, 83/367 (22.6%) were colonized by CPE. Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae complex were the most common CPE detected, with NDM as the predominant carbapenemase (78/90; 86.7%). Phenotypic resistance to meropenem was the best predictor of CPE production (sensitivity 85.6%, specificity 100%) compared with ertapenem resistance (95.6% sensitivity, 36% specificity). CIM was 100% concordant with PCR in detecting carbapenemases. These findings underscore the effectiveness of meropenem resistance as a robust indicator of the production of carbapenemases and the reliability of the CIM method to detect such carbapenemases in resource-limited settings where the performance of molecular methods is not possible.
- Open Access
Determination of glomerular filtration rate, a spin off after contrast-enhanced computed tomography among critically ill patients – proof of concept
Background: Recently, Gong et al. (Gong et al. 2022) showed, in nine heathy subjects, that plasma clearance of high doses of iohexol given as contrast enhanced computed tomography (CT) could be used for determination of glomerular filtration rate (GFR). We utilized high doses of iohexol from angiographic or other contrast enhanced CT given to critical ill patients for calculation of GFR iohexol and compared these data with standard low dose iohexol GFR determinations. Method: Patients at intensive care units (ICUs) in Southeast Sweden intended for radiographic investigations that included injection of 45-120 ml of iohexol (Omnipaque) were included, and the concentration of iohexol in plasma was measured by HPLC. Iohexol clearance was calculated by the method of Bröchner-Mortensen. The following days was iohexol clearance determined using the standard low dose of 5 mL of iohexol. Sixteen patients admitted to ICUs were included in this pilot study. Results: GFR after high dosing of iohexol at contrast enhanced CT could be measured for all sixteen critically ill patients. Patients with normal or increased renal function had neglectable iohexol concentrations the day following the CT scan. There was excellent correlation between GFR determination with high and standard low iohexol dosing among these 6 patients. Ten patients had decreased renal function and delayed elimination of iohexol, thus was not GFR measurement with low dose iohexol possible to analyse the day after CT scan with high dose iohexol. Conclusion: This pilot study showed that GFR can be measured after high doses of iohexol at enhanced CT and compare well with the standard low dose of iohexol clearance determinations.
Open AccessDetermination of glomerular filtration rate, a spin off after contrast-enhanced computed tomography among critically ill patients – proof of concept
Background: Recently, Gong et al. (Gong et al. 2022) showed, in nine heathy subjects, that plasma clearance of high doses of iohexol given as contrast enhanced computed tomography (CT) could be used for determination of glomerular filtration rate (GFR). We utilized high doses of iohexol from angiographic or other contrast enhanced CT given to critical ill patients for calculation of GFR iohexol and compared these data with standard low dose iohexol GFR determinations. Method: Patients at intensive care units (ICUs) in Southeast Sweden intended for radiographic investigations that included injection of 45-120 ml of iohexol (Omnipaque) were included, and the concentration of iohexol in plasma was measured by HPLC. Iohexol clearance was calculated by the method of Bröchner-Mortensen. The following days was iohexol clearance determined using the standard low dose of 5 mL of iohexol. Sixteen patients admitted to ICUs were included in this pilot study. Results: GFR after high dosing of iohexol at contrast enhanced CT could be measured for all sixteen critically ill patients. Patients with normal or increased renal function had neglectable iohexol concentrations the day following the CT scan. There was excellent correlation between GFR determination with high and standard low iohexol dosing among these 6 patients. Ten patients had decreased renal function and delayed elimination of iohexol, thus was not GFR measurement with low dose iohexol possible to analyse the day after CT scan with high dose iohexol. Conclusion: This pilot study showed that GFR can be measured after high doses of iohexol at enhanced CT and compare well with the standard low dose of iohexol clearance determinations.
- Open Access
Disease severity of unvaccinated SARS-CoV-2 positive adults less than 65 years old without comorbidity, in the Omicron period and pre-Omicron periods
Background The reduced severity and burden of COVID-19 in 2022 can largely be attributable to vaccination and a shift to Omicron predominance. However, millions of individuals remain unvaccinated. In the present study, we aimed to study disease severity in unvaccinated individuals without risk factors during the Omicron period, compared to pre-Omicron periods. Methods This register-based study included all unvaccinated individuals in Sweden aged 18-64 years without comorbidity or care dependency who were SARS-CoV-2 positive between week 45 of 2020 and week 5 of 2022. Variant of concern (VOC) periods were periods with certain VOCs identified in ≥92% of sequenced cases nationwide. Outcomes were hospitalization with a main discharge code of COVID-19; severe illness, defined as high-flow nasal oxygen treatment or intensive care unit admission; and death with COVID-19 as the underlying cause of death on the death certificate. Results Among 788,895 individuals in the overall SARS-CoV-2 positive cohort, both hospitalization and death increased stepwise from the pre-VOC period to the Alpha and Delta periods, and decreased in the Omicron period. Among 15,179 patients hospitalized for COVID-19, the proportions with severe illness and death increased to the Delta period, but in the Omicron period, these outcomes returned to the level of the pre-VOC period. Conclusion In the Omicron period, compared to pre-Omicron periods, unvaccinated SARS-CoV-2 positive adults <65 years old without comorbidity had reduced proportions of hospitalization and death overall, but similar proportion of severe illness among patients hospitalized for COVID-19. These results support continuous efforts to prevent hospitalizations for COVID-19.
Open AccessDisease severity of unvaccinated SARS-CoV-2 positive adults less than 65 years old without comorbidity, in the Omicron period and pre-Omicron periods
Background The reduced severity and burden of COVID-19 in 2022 can largely be attributable to vaccination and a shift to Omicron predominance. However, millions of individuals remain unvaccinated. In the present study, we aimed to study disease severity in unvaccinated individuals without risk factors during the Omicron period, compared to pre-Omicron periods. Methods This register-based study included all unvaccinated individuals in Sweden aged 18-64 years without comorbidity or care dependency who were SARS-CoV-2 positive between week 45 of 2020 and week 5 of 2022. Variant of concern (VOC) periods were periods with certain VOCs identified in ≥92% of sequenced cases nationwide. Outcomes were hospitalization with a main discharge code of COVID-19; severe illness, defined as high-flow nasal oxygen treatment or intensive care unit admission; and death with COVID-19 as the underlying cause of death on the death certificate. Results Among 788,895 individuals in the overall SARS-CoV-2 positive cohort, both hospitalization and death increased stepwise from the pre-VOC period to the Alpha and Delta periods, and decreased in the Omicron period. Among 15,179 patients hospitalized for COVID-19, the proportions with severe illness and death increased to the Delta period, but in the Omicron period, these outcomes returned to the level of the pre-VOC period. Conclusion In the Omicron period, compared to pre-Omicron periods, unvaccinated SARS-CoV-2 positive adults <65 years old without comorbidity had reduced proportions of hospitalization and death overall, but similar proportion of severe illness among patients hospitalized for COVID-19. These results support continuous efforts to prevent hospitalizations for COVID-19.
- 1 March 2022
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 22 (3) , 390-400
The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden
- 1 March 2022
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 22 (3) , 390-400
The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden
- Open Access
Disease severity related to VOC dominance in unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden
Although the emerging SARS-CoV-2 variants of concern (VOC) have shown increasing transmissibility, their role for causing severe disease has not been fully clarified. Here, we studied changes in rates of hospitalisation and severe illness (subjection to high-flow nasal oxygen or admission to an intensive care unit during hospital stay) among all (n=685 891) unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden from November 2020 to September 2021. After adjustment for age, sex, and socio-economic factors, and with November 2020 (non-VOC period) as reference, the odds ratios (OR) for hospitalisation were 1.6-1.7 in March-May 2021 (Alpha VOC dominance) and 2.4-3.0 in June-September 2021 (Delta VOC dominance), and the ORs for severe illness were 1.8-2.1 in March-May 2021 and 3.1-4.7 in June-September 2021. This study shows that unvaccinated adults without risk factors, have had a gradually increased risk for hospital admission and severe illness when infected with the Alpha and Delta VOCs, respectively.
Open AccessDisease severity related to VOC dominance in unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden
Although the emerging SARS-CoV-2 variants of concern (VOC) have shown increasing transmissibility, their role for causing severe disease has not been fully clarified. Here, we studied changes in rates of hospitalisation and severe illness (subjection to high-flow nasal oxygen or admission to an intensive care unit during hospital stay) among all (n=685 891) unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden from November 2020 to September 2021. After adjustment for age, sex, and socio-economic factors, and with November 2020 (non-VOC period) as reference, the odds ratios (OR) for hospitalisation were 1.6-1.7 in March-May 2021 (Alpha VOC dominance) and 2.4-3.0 in June-September 2021 (Delta VOC dominance), and the ORs for severe illness were 1.8-2.1 in March-May 2021 and 3.1-4.7 in June-September 2021. This study shows that unvaccinated adults without risk factors, have had a gradually increased risk for hospital admission and severe illness when infected with the Alpha and Delta VOCs, respectively.